Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 18, 2011

View Archived Issues

Neramexane mesilate is safe and well tolerated in subjects with tinnitus

RBC-mimicking hydrogel microparticles display improved biodistribution and circulation times

VKORC1 gene variations are associated with bone mineral density

MMRF and Synta Pharma to codevelop ganetespib for multiple myeloma

Lorus Therapeutics begins phase I trial of anticancer candidate LOR-253

Colesevelam has beneficial effects in patients with type 1 diabetes

Microtubule-associated protein 2 as a biomarker for traumatic brain injury

Bikam Pharmaceuticals presents new opsin ligands

New inhibitors of osteoclast differentiation/stimulation claimed

Vaximm obtains funding for phase I testing of VXM-01 vaccine

GSK patents new inhibitors of serotonin, dopamine and norepinephrine reuptake

Lilly and Boehringer Ingelheim enter global diabetes alliance

FDA agrees to SPA for phase III trials of netupitant/palonosetron as antiemetic

Epizyme and GSK join to develop agents targeting histone methyltransferases

GSK develops novel lysophospholipid S1P1 receptor agonists

Discovery Labs to prepare complete response to gain FDA approval for Surfaxin

Galapagos provides update on arthritis alliance with GSK

FDA approves new formulation of acetylcysteine injection

Risk of severe liver injury to be added to Multaq labels

Phase I trial to evaluate hydroxychloroquine to block autophagy in cancer

Phase I/II trial of Mologen's MGN-1601 in renal cancer cleared to admit all patients

Merck Serono and Domain Therapeutics join to develop agents for Parkinson's disease

Phase II trial of ADXS-11-001 in cervical dysplasia advances

Health Canada requests more information from Osiris regarding Prochymal approval

Bayer and Regeneron initiate phase III Asian trial of VEGF Trap-Eye

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...